Managing patients with ICD shocks and programming tachycardia therapies during acute heart failure syndromes
- First Online:
- Cite this article as:
- Bradfield, J., Tung, R., Boyle, N.G. et al. Heart Fail Rev (2011) 16: 449. doi:10.1007/s10741-011-9241-7
- 438 Downloads
We review the pharmacologic, interventional and device programming treatment options for patients with implantable cardioverter-defibrillators who present with acute heart failure and implantable cardioverter-defibrillator shocks.
KeywordsAcute heart failureImplantable cardioverter-defibrillatorShockAnti-tachycardia pacing
The management of implantable cardioverter-defibrillator (ICD) shocks and the programming of tachycardia therapies during acute heart failure syndromes is a topic of significant clinical importance, yet with limited data to guide evidence-based recommendations. Implantation of ICDs has been standard of care for resuscitated cardiac arrest and unstable ventricular arrhythmias since the 1990s, based on studies such as the Antiarrhythmics versus Implantable Defibrillators (AVID) trial [1, 2, 3]. Implantation of ICDs for primary prevention of sudden cardiac death in patients with left ventricular dysfunction became widely accepted after the MADIT II and SCD-HeFT studies were published in 2002 and 2005, respectively [4, 5].
Previous studies have shown that patients who receive appropriate ICD therapy are at higher risk for heart failure hospitalizations and mortality . However, for ICD shocks occurring in the setting of acute heart failure, decisions regarding ICD programming as well as medical and interventional therapy are often based on small studies, expert opinion or personal experience within the cardiac electrophysiology community.
After correcting volume overload, titrating up to the maximum tolerated beta blocker dose is an essential medical intervention. Besides reducing hospitalizations and mortality, higher doses of beta blockers appear from the MADIT-II trial to decrease the frequency of ventricular tachycardia (VT) and ventricular fibrillation (VF) requiring ICD shocks .
There is some concern that high-dose beta blockers may lead to more ventricular pacing, resulting in dyssynchrony and possibly a further decrease in ventricular function. However, in the acute setting, the focus should be on the management of ventricular arrhythmias and patient symptoms, including shocks. In the longer term, if optimal beta blocker dose results in obligate univentricular pacing, consideration can be given to upgrading to a cardiac resynchronization (CRT) device for improved ventricular synchrony.
Although ICD therapy is life-saving, patients presenting with recurrent ICD therapy and no reversible cause frequently require antiarrhythmic drugs to decrease the frequency of shocks. The primary indication for antiarrhythmic drug therapy in ICD patients is VT. However, inappropriate shocks due to rapid supraventricular arrhythmias, can account for up to 27% of all shocks delivered to ICD patients based on data from SCD-HeFT . Such inappropriate shocks were also associated with increased mortality in this population. Aggressive treatment of supraventricular arrhythmias is important as well.
In the presence of underlying cardiomyopathy, both ischemic and non-ischemic, the choice of antiarrhythmic medications is limited. Data from the CAST trial  demonstrated increased mortality associated with the use of class IC agents such as flecainide in the treatment of ventricular ectopy in patients with prior myocardial infarction. Sotalol is a class III agent not recommended in the setting of severe cardiomyopathy based on data from studies such as the SWORD trial . However, it is still frequently used as a second line agent if an ICD is already present. A study by Pacifico and colleagues demonstrated a significant reduction in frequency of shocks in patients treated with sotalol . Furthermore, sotalol may decrease the defibrillation threshold , and therefore may be a reasonable choice in patients requiring antiarrhythmic therapy who also demonstrate elevated defibrillation threshold.
Studies on amiodarone and dofetilide, both class III agents, show no evidence of increased mortality in heart failure patients. A recent meta-analysis demonstrated a statistically significant decrease in sudden cardiac death (SCD) and cardiovascular death in patients treated with amiodarone . However, there is no evidence suggesting decreased all-cause mortality with amiodarone therapy from large controlled trials . Amiodarone added to a beta blocker has been shown to significantly decrease ICD shocks compared to beta blocker alone or sotalol . There is appropriate concern regarding amiodarone use in younger patients due to the risk of long-term side effects.
Dofetilide may be an alternative based on the DIAMOND-CHF study . In this study, the dofetilide group had fewer hospitalizations as well as improved rhythm control in the subset of patients with atrial fibrillation. Torsades de pointes did occur in 3.3% of patients in the dofetilide group versus none in the placebo group, so this drug may not be appropriate in patients without a previously placed ICD. Due to its renal clearance, use of this medication is often limited by renal insufficiency, and the requirement for in-hospital initiation of the drug is another significant limitation.
Dronedarone is a new antiarrhythmic drug chemically similar to amiodarone, but lacking the iodine moiety appears to have less thyroid and pulmonary toxicity. It is contraindicated in the setting of severe heart failure based on the results of the ANDROMEDA study, which demonstrated an increased mortality due to worsening heart failure in the treatment group . However, it was shown to decrease hospital admissions and overall mortality in patients with atrial fibrillation, and mild to moderate heart failure in the ATHENA trial .
In the ischemic cardiomyopathy population, ischemia may exacerbate acute heart failure and associated arrhythmias. Prompt assessment and treatment of unstable or flow-limiting coronary stenosis should be undertaken. Acute ischemia is an uncommon cause of monomorphic VT, which is more commonly related to reentry associated with ventricular scar from chronic myocardial infarction or fibrosis from underlying non-ischemic cardiomyopathy. Acute ischemia more commonly causes polymorphic VT or ventricular fibrillation. However, if the ischemia causes worsening heart failure and volume overload, it can lead to increased frequency of all types of ventricular arrhythmias and therefore should be treated aggressively.
Other non-device-related interventions can also be helpful in the setting of recurrent ICD shocks during an acute heart failure exacerbation. Intra-aortic balloon counterpulsation may help reduce afterload, improve coronary perfusion, and relieve acute ischemia, aiding the stabilization of recurrent arrhythmias.
Patients admitted with an acute heart failure exacerbation and recurrent ICD shocks resistant to medical and invasive interventions may require intubation and sedation, both for patient comfort and to decrease the sympathetic surge associated with ventricular arrhythmias. The potential role of the sympathetic nervous system in the initiation and maintenance of ventricular arrhythmias must be considered [19, 20]. Schwartz and colleagues [21, 22, 23] demonstrated that left cardiac sympathetic denervation increases ventricular refractoriness and raises ventricular fibrillation threshold. Deep sedation may beneficially decrease the elevated adrenergic tone seen in this patient population. Other potential treatment options that reduce cardiac sympathetic stimulation are still being assessed, including thoracic epidural anesthesia and left cardiac sympathetic denervation [24, 25]. These interventions are potential future treatment options with promising early results.
Initial ICD management and programming in the setting of acute heart failure should involve assessment of the system to ensure appropriate device and lead function, and to rule out lead fracture, insulation defects, or dislodgement. Stored events should be assessed to determine if appropriate therapies were delivered for ventricular arrhythmias, or if inappropriate shocks resulted from supraventricular tachycardia (SVT), T wave or QRS double counting, electromagnetic or myopotential oversensing, or noise such as from a loose set screw or lead fracture. Once appropriate device function has been confirmed, the arrhythmia events can be analyzed to guide further decisions on programming and treatment options.
Patients implanted with an ICD for primary prophylaxis of sudden cardiac death are often programmed with empiric VT and VF zones based on age and physician preference. Patients with significant ventricular scar, especially those taking antiarrhythmic drugs, can develop relatively slow VT which may fall outside the selected VT detection and treatment zones.
When such a scenario is identified, a reasonable first response is to reprogram the VT zone to a longer cycle length to ensure therapy for the clinical tachycardia. If the tachycardia is hemodynamically tolerated, attempts should be made to treat with anti-tachycardia pacing (ATP) as initial therapy to avoid shocks. Further, the number of ventricular beats in a given zone needed to define a detection of VT episode should be high enough to avoid treating non-sustained events.
It is still debated whether ICD shocks are simply a marker of worsening underlying cardiomyopathy, or whether the shock itself directly contributes to worsened outcomes. There are data showing myocardial damage from ICD shocks [26, 27]. Further, a recent analysis by Sweeney and colleagues reviewing device therapy trials found that patients receiving shocks compared to ATP had increased mortality after controlling for other known risk factors, suggesting that the shock itself contributed to increased mortality. In combination with previous evidence from MADIT-II and SCD-HeFT showing increased mortality after appropriate shocks [6, 9, 29], this suggests that aggressive programming of ATP in the fast VT zone as in the PAINFREE  and PAINFREE II trials  is safe and reasonable. In a recent study , Bhavnani and colleagues used multivariate analysis to compare shocks for device testing with shocks for clinical arrhythmias. Although there was no increased mortality associated with shocks done to test device sensing and defibrillation threshold (DFT), mortality was higher in patients with appropriate shocks, suggesting that the underlying substrate plays a significant role in outcomes and not simply the shock itself.
While there is evidence that ICD shocks can be deleterious to cardiac function, one can also make the argument that clinical VT unresponsive to previous ATP therapy may be better treated with immediate shock. If ATP is not successful, the cumulative time spent in VT will increase, and this may also predict worse outcomes . Therefore, for patients that do not respond to ATP for a given sustained tachyarrhythmia, an immediate shock may be the best treatment option.
Results of the DAVID trial  demonstrated that high rates of univentricular pacing increased the combined endpoint of death or hospitalization for heart failure. Given this data, devices should be programmed to minimize unnecessary ventricular pacing. Programming changes, including decreasing base pacing rate and increasing atrioventricular (AV) interval in patients with dual chamber devices should be considered. This is of particular importance if device interrogation demonstrates that an increase in ventricular pacing correlates with the heart failure episode. This must of course be considered along with the patient’s tolerance of slower ventricular rates. If increased need for ventricular pacing is due to progression of underlying conduction system disease or is a response to necessary high-dose beta blockade, the addition of a coronary sinus lead for more optimal intraventricular synchrony with biventricular pacing should be considered.
Patients frequently undergo defibrillation threshold testing (DFT) at or near the time of ICD implantation to assess detection and therapy for ventricular fibrillation (VF). While DFT testing remains standard for both primary and secondary prevention device implants, many cardiac electrophysiologists are now omitting DFT testing for primary prevention patients. This is based on large part of published trials demonstrating high defibrillation success rates with newer devices (97.8% in the SCD-HeFT trial) and a small but concerning risk associated with DFT testing itself. In addition, the correlation between defibrillation threshold at implantation (prolonged anesthesia, supine position, induced VF), and real-world clinical VT or VF is unclear. In long-term follow-up, initial shocks for clinical ventricular arrhythmias had a success rate of 80–100% regardless of implant DFT . While infrequent, patients with adequate safety margin DFT at implant testing (usually 10 joules), may develop recurrent ventricular arrhythmias refractory to ICD therapies in the setting of acute heart failure. Management of these cases necessitates aggressive medical management of the acute heart failure and volume overload with consideration for repeat DFT testing and possible ICD system revision, prior to discharge to ensure successful therapy in the future.
Unsuccessful defibrillation after a clinical ventricular arrhythmia may require changes to the defibrillator system. Non-invasive options include repeat DFT testing utilizing alternative shocking vectors, which in an individual patient may provide a lower DFT. Invasive options include addition of a new RV pace/sense lead if sensing of VF is the issue, or addition of a new RV shocking lead if the current lead is dysfunctional or in a suboptimal position. Addition of a subcutaneous array, SVC coil, or azygous vein lead  may also be considered to alter the shocking vector and include more of the left ventricle (LV) in the shocking field.
Evaluation of device proarrhythmia
Biventricular ICDs and pacemakers have been demonstrated to improve NYHA functional class, decrease heart failure hospitalizations, and decrease mortality in properly selected patients [36, 37]. However, case reports and case series have demonstrated the potential proarrhythmic effects of biventricular devices [38, 39]. These events are relatively rare, and proposed mechanisms include increased dispersion of refractoriness, prolonged QT interval, and atypical autonomic response. The LV lead may induce premature ventricular beat triggers or activate scar-related regions of slow conduction to facilitate reentry. Such atypical responses are infrequent and there are no clear predictors of such a response. However, if a patient presents with heart failure and ventricular arrhythmias after a recent biventricular device implantation, it is reasonable to consider temporarily discontinuing LV pacing to determine if this will decrease arrhythmic events, which has been demonstrated in some case series .
Catheter ablation of VT is moving from a palliative procedure to being used as an earlier preemptive treatment strategy. Recent studies showing improved clinical efficacy (up to 75% success at 1 year) and acceptable complication rates given the high-risk substrate, include the Multicenter Thermocool Ventricular Ablation trial  and the Substrate Mapping and Ablation in Sinus Rhythm to Halt Ventricular Tachycardia trial (SMASH VT) . This evolving role for VT ablation is reflected in the recently published EHRA/HRS Expert Consensus on Catheter Ablation of Ventricular Arrhythmias . While acute heart failure admission was not an exclusion criterion for THERMOCOOL and SMASH-VT, no ablation studies to date have sought to enroll patients specifically in the setting of acute heart failure .
Atrial fibrillation (AF) frequently coexists with ventricular arrhythmias in the cardiomyopathy population. Atrial fibrillation with rapid ventricular rates can lead to ICD shocks despite algorithms meant to differentiate it from VT. Use of a dual chamber device and various atrial fibrillation discrimination algorithms can help but are not fail-safe. When medical therapy fails, consideration can be given to atrial fibrillation ablation. If the AF is refractory to ablation or the patient is not a candidate, and the rate cannot be adequately controlled, then AV nodal ablation with biventricular pacing is an alternative .
Responding to ICD shocks and programming ICD therapies in the setting of acute heart failure involves a combination of medical, interventional, and device-based interventions. Cardiac electrophysiologists and heart failure specialists must work in collaboration to optimize the underlying substrate, treat precipitating factors and program the patient’s device to ensure successful therapy while minimizing the number of ICD shocks.
This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.